Mutations in the DJ-1, PRKN, and PINK1 genes might present with a similar phenotype, characterized by an age at onset of 25 to 30 years, mild nonmotor symptoms, and a tendency to develop dyskinesia and dystonia in response to even minimal doses of levodopa, which may be optimally treated with STN DBS.42 This evidence concerns the gene PINK1 and Dystonia.